Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial

BACKGROUND: EXamining everolimus In a Study of Tuberous sclerosis 3 (EXIST-3) demonstrated significantly reduced seizure frequency (SF) with everolimus vs placebo. In this study, we evaluate the long-term efficacy and safety of everolimus for tuberous sclerosis complex (TSC)-associated treatment-ref...

Descripción completa

Detalles Bibliográficos
Autores principales: Franz, David N., Lawson, John A., Yapici, Zuhal, Ikeda, Hiroko, Polster, Tilman, Nabbout, Rima, Curatolo, Paolo, de Vries, Petrus J., Dlugos, Dennis J., Voi, Maurizio, Fan, Jenna, Vaury, Alexandra, Pelov, Diana, French, Jacqueline A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276348/
https://www.ncbi.nlm.nih.gov/pubmed/30564495
http://dx.doi.org/10.1212/CPJ.0000000000000514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276348/
https://www.ncbi.nlm.nih.gov/pubmed/30564495
http://dx.doi.org/10.1212/CPJ.0000000000000514

Ejemplares similares